Clinicopathological features of anti-HMGCR and anti-SRP myopathies that do not satisfy the European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) criteria of inflammatory myopathies
Authors' conclusion
Some IMNM cases showing a clinicopathologically mild phenotype and a benign course cannot be classified as IIMs by the EULAR/ACR classification criteria, and antibody testing is crucial for accurate diagnosis.
Study context
- Population
- Anti-HMGCR antibody-positive and anti-SRP antibody-positive cases (immune-mediated necrotizing myopathy (IMNM))71 anti-HMGCR+, 94 anti-SRP+
- Exposure
- Cases not classified as idiopathic inflammatory myopathies (IIMs) (<possible group) vs cases classified as IIMs (definite-possible group) by the EULAR/ACR classification criteria
- Outcome
- Classification as <possible group
Main finding
As reported in the abstract
Anti-HMGCR antibody-positive cases classified as <possible
19
26%
Anti-SRP antibody-positive cases classified as <possible
19
20%
Observational data: associations, not effects.
Further findings
Reclassification during follow-up (up to 24 months) in the <possible group
- Followed-up <possible cases later classified as definite-possible
- 3 of 26
- Other followed-up cases remained in the <possible group
Original publication
Clinicopathological features of anti-HMGCR and anti-SRP myopathies that do not satisfy the EULAR/ACR criteria of inflammatory myopathies. Rheumatology (Oxford). Published 3 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →